Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis

Summary

This is a randomized, controlled study evaluating empagliflozin tablets administered daily for 8 weeks. The purpose of the study is to evaluate the efficacy and safety of empagliflozin in the treatment of mild to moderately active ulcerative colitis. Disease activity will be measured using Mayo score for ulcerative colitis activity. Calculation of the score requires patients to undergo colonoscopy at the start of the study and at week 8.

Timeline

Start

2021-10-01

Primary completion

2025-09-30

Completion

2025-12-31

Drugs

Indications